trial

A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia

NCTId NCT01812642
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 33 (actual)
Sponsored by Johnson & Johnson
Primary completion 2008-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
33 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-07
Primary completion
2008-12
Eligibility
ALL · 20 Years · 55 Years

Interventions & indications

Drugs
JNJ-37822681

Sponsors

Johnson & JohnsonLead Sponsor

Sites

0 total

Linked catalysts

1
A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in — primary completion2008-12

Facts & assertions

4 sourced
Enrollment
33
Phase
PHASE2
Primary Completion Date
2008-12
Status
COMPLETED
relationships
The graph out of here
drug
JNJ-37822681
drug
lead_sponsor
Johnson & Johnson
company
indication
Schizophrenia
indication
Schizophrenia
indication